Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesGenetic & Molecular TestingBlue Cross Blue Shield RI PLA/MAAA Coverage Prior …
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

    Proprietary Laboratory Analyses (PLA) and Multianalyte Assays with Algorithmic Analyses (MAAA)

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - Rhode Island policy alerts

    Know when Blue Cross Blue Shield - Rhode Island releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines coverage, medical necessity criteria, and prior authorization requirements for proprietary genetic and multianalyte laboratory tests (PLA/MAAA) for BCBSRI members, applying to Medicare Advantage and Commercial Products.

    Policy Summary
    PayerBlue Cross Blue Shield - Rhode Island
    PolicyProprietary Laboratory Analyses (PLA) and Multianalyte Assays with Algorithmic Analyses (MAAA)
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage changes
    Effective DateJun 1, 2026
    Last ReviewJan 4, 2026
    Next Review DateJan 4, 2026
    Key ActionSubmit prior authorization requests via the BCBSRI online prior authorization tool; fax to Utilization Management at (401) 272-8885 if the test is not listed.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    PLA & MAAA included

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    coding grid
    MA prior auth requiredprior auth rule
    Exemption effective 10/1/2025PCP exemption
    InterQual usedclinical criteria source
    Panels may be not coveredpanel coverage risk

    Coverage and Medical Necessity Criteria

    Medical necessity criteria

    Covered when ALL of the following general conditions are met (examples provided):

    General genetic testing medical necessity: Genetic screening or testing is medically necessary when testing the individual's germline will benefit the individual and one of: confirm a suspected diagnosis in a patient with signs and/or symptoms; identify a causative etiology for a clinical syndrome with multiple possible underlying conditions; or test an asymptomatic individual to determine future disease risk.

    InterQual criteria is used in the online authorization tool for many determinations.

    Carrier screening (preconception or prenatal): Carrier screening is medically necessary when ALL of the following are met: one or both individuals have a first- or second-degree relative who is affected; one individual is a known carrier; one or both individuals are from a population with an elevated carrier rate for the condition; AND previous carrier screening or targeted testing for the gene variant(s) of interest has not been performed.

    First- and second-degree relatives are defined in policy (first-degree: biological parent, brother, sister, child; second-degree: grandparent, aunt, uncle, niece, nephew, grandchildren, half-sibling).

    Cancer-related genetic testing: Genetic testing for cancer is medically necessary when ONE of the following is met: testing an asymptomatic patient to determine future cancer risk; or therapeutic (somatic) testing of tumor/cancer cells to direct targeted treatment based on specific somatic variants.

    Services are not covered for Medicare Advantage Plans and are not medically necessary for Commercial Products when there is insufficient clinical evidence, results would not reasonably be used in patient management, or services are unlikely to impact therapeutic decision-making. Laboratories are not permitted to obtain authorizations or participate in the authorization process on behalf of the ordering physician; only the ordering physician may be involved in authorization, appeal, or other administrative processes.

    Some Commercial Product members may also be subject to contract exclusions for expanded biomarker testing per plan-specific benefit booklets and the Biomarker Testing Mandate policy; refer to the Coding section and the member's benefit booklet for plan-specific coverage determinations.

    An entire genetic panel test is considered not covered for Medicare Advantage Plans and not medically necessary for Commercial Products when there is insufficient evidence that the panel or the specific gene/variant would influence treatment decisions and improve net health outcomes. When evidence is lacking that any component of a panel will change management, the entire panel may be denied; for specific panel components filed with individual CPT codes, refer to the attached code grid and the Genetic Testing Services policy for coverage guidance.

    Covered Indications

    Covered indications — Examples of appropriate uses

    Confirmatory diagnostic testing: Testing to confirm a suspected genetic diagnosis in a patient who has signs and/or symptoms consistent with the condition.
    Etiology identification for syndromic presentations: Testing to identify a causative etiology for a clinical syndrome that has multiple possible underlying genetic causes.
    Asymptomatic risk assessment: Asymptomatic testing of an individual to determine future disease or cancer risk (predictive/proactive germline testing).
    Somatic tumor testing: Therapeutic somatic (tumor) testing to direct targeted therapy based on identification of specific somatic variants that would benefit the individual.

    Coding and Billing

    PLA/MAAA Coding Gridmixed
    see attached gridDetailed PLA/MAAA CPT codes and coverage status are listed in the attached code grid referenced by the policy.
    Carrier screening prior criteria — eligibility conditions
    Eligibility — family historyOne or both individuals have a first- or second-degree relative who is affected (first-degree: parent, brother, sister, child; second-degree: grandparent, aunt, uncle, niece, nephew, grandchild, half‑sibling)
    Eligibility — known carrierOne individual is a known carrier for the condition being screened
    Eligibility — elevated population riskOne or both individuals are members of a population with a carrier rate that exceeds the threshold appropriate for testing for that condition
    Prior testing requirement (actionable)Previous carrier screening or individual targeted gene testing for the gene variant(s) of interest must not have been performed
    Context — test settingApplies to carrier screening in the preconception or prenatal setting

    Provider Actions and Authorization Requirements

    Prior Authorization

    Prior authorization required for grid-listed tests

    Prior authorization is required for tests listed in the attached PLA/MAAA code grid for Medicare Advantage Plans and is recommended for Commercial Products; for panel testing, each CPT code component must be entered and processed separately through the online authorization tool.

    • Prior authorization required for Medicare Advantage Plans; recommended for Commercial Products.
    • Panel testing: each component/gene represented by multiple CPT codes requires a separate prior authorization entry and processing.
    Prior Authorization

    PCP exemption for Fully‑Funded Commercial Products (effective 10/1/2025)

    Effective 10/1/2025, Fully-Funded Commercial Products may exempt prior authorization when the requesting physician is an in‑network BCBSRI contracted primary care provider in one of the listed specialties (Internal Medicine; Pediatric Medicine; Family Practice; Obstetrics and Gynecology; DO; NP/PCP; PA). This exemption does not apply to Self‑Funded Commercial Products or Medicare Advantage Plans.

    Member Eligibility Requirements

    Coverage of proprietary genetic and multianalyte laboratory tests requires that the requested testing meet the medical necessity criteria used in the online authorization tool (InterQual) and any additional panel-specific criteria described in this policy. For carrier screening (preconception or prenatal), the policy requires that one or both individuals have a first- or second-degree relative affected, or one individual is a known carrier, or the individuals belong to a population with an elevated carrier rate, and that previous carrier screening or targeted testing for the variant(s) of interest has not been performed.

    General eligibility for genetic testing is limited to situations where testing of an individual's germline will provide clinical benefit, such as to confirm a suspected diagnosis in a symptomatic patient, to identify a causative etiology for a clinical syndrome with multiple possible causes, or to assess future disease or cancer risk in an asymptomatic individual. Panel tests remain subject to additional policy criteria and prior authorization requirements.

    Not Covered Services

    Panels and multigene tests are not covered when there is insufficient evidence that the results would impact clinical management or improve net health outcomes. In such cases the entire panel may be denied for Medicare Advantage and deemed not medically necessary for Commercial Products. Additionally, certain genetic testing services may be explicit contract exclusions for some self-funded Commercial groups; check the member's benefit booklet and the Coding section of this policy for plan-level exclusions.

    Background

    Proprietary Laboratory Analyses (PLA) are alphanumeric CPT descriptors used for proprietary clinical laboratory tests; they may be issued for a single-source laboratory or licensed to multiple laboratories. PLA and Multianalyte Assays with Algorithmic Analyses (MAAAs) may or may not be FDA-cleared and are often unique to a particular laboratory or manufacturer. These assays combine multiple analyte results and apply algorithmic analysis to produce a score or probability; they are subject to the same medical necessity, coding, and prior authorization requirements outlined in this policy.

    Panel testing increases breadth of testing but may also increase the yield of variants of uncertain significance and potential harm if results would not change clinical management; therefore panel tests are subject to additional criteria and review in the online authorization tool.

    Key Definitions

    PLA code — definition and precedence
    PrecedenceWhen a PLA code is available to report a given proprietary laboratory service, that PLA code takes precedence and should be used instead of other CPT codes for the same service
    Reporting ruleServices reported with a PLA code should not be reported using any other CPT code(s)
    Availability requirementThe test must be commercially available in the U.S. for use on human specimens and requested by the clinical laboratory or manufacturer
    Regulatory notePLA codes do not require adherence to CPT Category I criteria or AMA review for clinical utility and may or may not be FDA approved
    MAAA — definition and examples
    DefinitionMultianalyte Assays with Algorithmic Analyses (MAAAs) utilize multiple results from panels of various assay types (molecular, FISH, non–nucleic acid assays such as proteins) and apply algorithmic analysis to produce numeric scores or probabilities

    Revision History

    2026-06-01effective_dateLatest

    Policy effective date set to 06/01/2026.

    2026-04-01last_review

    Policy last reviewed on 04/01/2026.

    2026-01-01publication

    Provider Update published January/February 2026 referencing this policy.

    Policy Summary
    PayerBlue Cross Blue Shield - Rhode Island
    PolicyProprietary Laboratory Analyses (PLA) and Multianalyte Assays with Algorithmic Analyses (MAAA)
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage changes
    Effective DateJun 1, 2026
    Last ReviewJan 4, 2026
    Next Review DateJan 4, 2026
    Key ActionSubmit prior authorization requests via the BCBSRI online prior authorization tool; fax to Utilization Management at (401) 272-8885 if the test is not listed.
    SourceLink
    On This Page
    Coverage and Medical Necessity CriteriaCovered IndicationsCoding and BillingProvider Actions and Authorization RequirementsMember Eligibility RequirementsNot Covered ServicesBackgroundKey DefinitionsRevision History
  1. Applies only to Fully‑Funded Commercial Products and only when the requesting physician is a BCBSRI contracted PCP in the specified specialties.
  2. Prior authorization still required for Self‑Funded Commercial Products and Medicare Advantage Plans.
  3. Note

    Ordering physician must control authorization and administrative processes

    Only the ordering physician must initiate and be involved in the authorization, appeal, or administrative processes for genetic testing; laboratories and third parties are not permitted to obtain clinical authorization or act on behalf of the ordering clinician.

    • The ordering physician shall be the sole party involved in authorization, appeals, or related administrative tasks.
    • Laboratories may not obtain authorization or participate in the authorization process on behalf of the ordering physician.
    Documentation Required

    How to submit prior authorization

    Submit prior authorization requests using the BCBSRI online prior authorization tool (available to BCBSRI‑participating providers). Providers who do not have access to the online tool must fax requests to Utilization Management at (401) 272‑8885. If a genetic test is not found in the online tool, fax the request to Utilization Management at (401) 272‑8885.

    • Use BCBSRI online prior authorization tool for participating providers.
    • Fax non‑participating provider requests or requests for tests not listed in the online tool to Utilization Management at (401) 272‑8885.
    Denial Risk

    Prohibition on laboratory/third‑party obtaining or supporting authorization

    If a laboratory or any third party obtains authorization on behalf of the ordering physician, assists in the authorization process, or prepares documentation supporting authorization/appeal, BCBSRI will deem this a policy violation and may take severe action up to termination from the BCBSRI provider network; services provided without authorization may be denied as the financial liability of the participating laboratory and may not be billed to the member.

    • Laboratory/third‑party obtaining or supporting authorization is a policy violation subject to severe action, up to termination.
    • Unauthorized laboratory services may be denied and billed to the laboratory rather than the member.
    Denial Risk

    Missing required prior authorization will lead to denial

    Services for which prior authorization is indicated in the attached code grid will be denied if the required authorization is not obtained; when a panel is represented by multiple CPT codes, each component without its own authorization entry may be denied.

    • Missing prior authorization for grid‑listed services will result in denial.
    • Panel components represented by multiple CPT codes each require individual authorization; missing entries may be denied per component.
    Documentation Required

    Ordering physician responsibility for authorization and appeals

    Ensure the ordering physician initiates authorization requests and remains the point of contact for authorization, appeals, and administrative communications; do not rely on laboratories or third parties to manage authorizations.

    • Ordering physician must be the party to request and manage authorization and any appeals.
    • Laboratories and third parties must not be used to obtain or facilitate authorizations.
    Billing Rule

    Laboratories may not obtain authorization on behalf of ordering clinicians

    Only the ordering physician shall be involved in authorization, appeal, or administrative processes; laboratories are explicitly not allowed to obtain clinical authorization or participate in the authorization process on behalf of the ordering physician.

    • Laboratories cannot obtain authorization, facilitate the authorization process, or prepare documentation of clinical appropriateness on behalf of the ordering clinician.
    • Violations are subject to severe action by BCBSRI, including termination from the provider network.
    Typical sourceMAAAs are typically unique to a single clinical laboratory or manufacturer
    InputsMay include molecular pathology assays, fluorescent in situ hybridization assays, and non‑nucleic acid‑based assays (e.g., proteins, polypeptides, lipids, carbohydrates); other patient information may also be incorporated
    OutputAlgorithmic analysis is reported typically as a numeric score(s) or a probability used to inform clinical decision‑making
    Relation to panelsMAAAs and genetic panels can increase breadth of testing but may yield variants of uncertain significance that do not change management
    2025-10-01coverage_change_effective

    PCP exemption for prior authorization in Fully-Funded Commercial Products effective 10/01/2025.

    2025-01-01publication

    Provider Update issues published in 2025 (Jan/Feb/May/July/Sep/Nov) referencing ongoing policy communications.